References
- Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573–585.
- de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA.. 1998;95:322–327.
- Sakurai T. Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med Rev. 2005;9:231–241.
- Suvorexant FDA Approval. 2014. US Food & Drug Administration: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=204569 [cited 2017 Dec 20]
- Modafinil FDA Approval. 1998. US Food & Drug Administration: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil.cfm [cited 2017 Dec 20]
- Bennett T, Bray D, Neville MW. Suvorexant, a dual orexin receptor antagonist for the management of insomnia. P T. 2014;39:264–266.
- Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79:2265–2274.
- Kuriyama A, Tabata H. Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis. Sleep Med Rev. 2017;35:1–7.
- Golicki D, Bala MM, Niewada M, et al. Modafinil for narcolepsy: Systemic review and meta-analysis. Med Sci Monit. 2010;16:177–186.
- Ishizuka T, Murotani T, Yamatodani A. Modafinil activated the histaminergic system through the orexinergic neurons. Neurosci Lett. 2010;483:193–196.
- Spiller HA, Borys D, Griffith JR, et al. Toxicity from modafinil ingestion. Clin Toxicol (Phila). 2009;47:153–156.
- Carstairs SD, Urquhart A, Hoffman J, et al. A retrospective review of supratherapeutic modafinil exposures. J Med Toxicol. 2010;307–310.
- Bronstein AC, Spyker DA, Cantilena LR, Jr, et al. 2011 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS) 29th annual report. Clin Toxicol. 2012;50:911–1164.